Efficacy and safety of rimegepant for the preventive treatment of migraine in Japan: A double‐blind, randomized controlled trial
This study tested the effectiveness of rimegepant for migraine prevention in Japan. Results showed that rimegepant was more effective than placebo in reducing monthly migraine days, with very few adverse effects. These results support the previous findings from a clinical study conducted in the United States and broaden them to a wider population.
Authors
- Fumihiko Sakai (ORCID: https://orcid.org/0000-0001-9385-7991)
- Akio Arakawa
- Takao Takeshima (ORCID: https://orcid.org/0000-0003-2678-6956)
- Tomofumi Ishikawa (ORCID: https://orcid.org/0000-0002-0901-368X)
- Shigekazu Kitamura (ORCID: https://orcid.org/0000-0001-7162-4265)
- Robert Croop (ORCID: https://orcid.org/0009-0004-0151-1192)
- Terence Fullerton
- Alexandra Thiry
- Toshimasa Yamamoto (ORCID: https://orcid.org/0009-0005-1171-6244)
- Hiroki Yoshimatsu
- Yasuhiko Matsumori (ORCID: https://orcid.org/0000-0001-5852-0146)
- Yuko Hoshino
Institutions
- Miyagi University of Education (JP)
- Konan University (JP)
- Pfizer (United States) (US)
- Tominaga hospital (JP)
- Biohaven Pharmaceuticals (United States) (US)
- Pfizer (Japan) (JP)
- Saitama Medical University (JP)
Publication Details
- Journal
- Headache The Journal of Head and Face Pain
- Published
- 2025-06-20
- DOI
- https://doi.org/10.1111/head.14995
- Citations
- 9
- Primary Topic
- Migraine and Headache Studies
- Type
- article
- Field-Weighted Citation Impact
- 13.24
Funders
- Pfizer